MX383462B - Pridopidina para el tratamiento de las discinesias inducidas por fármacos - Google Patents

Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Info

Publication number
MX383462B
MX383462B MX2020002645A MX2020002645A MX383462B MX 383462 B MX383462 B MX 383462B MX 2020002645 A MX2020002645 A MX 2020002645A MX 2020002645 A MX2020002645 A MX 2020002645A MX 383462 B MX383462 B MX 383462B
Authority
MX
Mexico
Prior art keywords
drug
subject
pridopidine
induced
treatment
Prior art date
Application number
MX2020002645A
Other languages
English (en)
Spanish (es)
Other versions
MX2020002645A (es
Inventor
Aric Orbach
Michael Hayden
Michal Geva
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2020002645A publication Critical patent/MX2020002645A/es
Publication of MX383462B publication Critical patent/MX383462B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2020002645A 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos MX383462B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556314P 2017-09-08 2017-09-08
US201862649184P 2018-03-28 2018-03-28
PCT/US2018/048920 WO2019050775A1 (en) 2017-09-08 2018-08-30 PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Publications (2)

Publication Number Publication Date
MX2020002645A MX2020002645A (es) 2021-06-10
MX383462B true MX383462B (es) 2025-03-14

Family

ID=63684481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002645A MX383462B (es) 2017-09-08 2018-08-30 Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Country Status (10)

Country Link
US (2) US20190231768A1 (https=)
EP (1) EP3678664A1 (https=)
JP (1) JP2020533296A (https=)
CN (1) CN111343982A (https=)
AU (1) AU2018329628B2 (https=)
BR (1) BR112020004622A2 (https=)
CA (1) CA3075020C (https=)
IL (1) IL273044A (https=)
MX (1) MX383462B (https=)
WO (1) WO2019050775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CN113395964A (zh) 2019-02-04 2021-09-14 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
KR102906269B1 (ko) 2023-08-03 2026-01-02 재단법인대구경북과학기술원 파킨슨 환자의 lid 발병 예측을 위한 정보제공방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101711236B (zh) 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
WO2008155357A2 (en) * 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
BR112014005389A8 (pt) 2011-09-07 2018-04-03 Ivax Int Gmbh Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶（ｐｒｉｄｏｐｉｄｉｎｅ）之氫溴酸鹽
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
HK1221646A1 (zh) 2013-06-21 2017-06-09 Teva Pharmaceuticals International Gmbh 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
DK177976B8 (en) 2013-07-10 2021-04-22 Jasopels As Apparatus and method for stretching a pelt on a pelt board
MX377576B (es) 2014-01-22 2025-03-04 Prilenia Neurotherapeutics Ltd Formulaciones de pridopidina de liberación modificada.
JP6526695B6 (ja) 2014-03-10 2019-06-26 アプライド マテリアルズ インコーポレイテッドＡｐｐｌｉｅｄ Ｍａｔｅｒｉａｌｓ，Ｉｎｃｏｒｐｏｒａｔｅｄ 多重荷電粒子ビームリソグラフィのためのピクセルブレンディング
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
JP7034488B2 (ja) 2016-02-24 2022-03-14 プリレニア・ニューロセラピューティクス・エルティーディー プリドピジンを使用する神経変性眼疾患の治療
CA3035099C (en) 2016-08-24 2023-01-17 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating dystonias
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
CN109952100A (zh) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗焦虑和抑郁的用途
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
SI4154882T1 (sl) 2017-08-14 2026-01-30 Prilenia Neurotherapeutics Ltd. Zdravljenje amiotrofične lateralne skleroze s pridopidinom
CA3073568A1 (en) * 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
DE102018204527A1 (de) 2017-09-18 2019-03-21 SEs Solutions GmbH Dachhalterung für ein Automobil

Also Published As

Publication number Publication date
US20190350914A1 (en) 2019-11-21
AU2018329628A1 (en) 2020-04-16
IL273044A (en) 2020-04-30
US20190231768A1 (en) 2019-08-01
EP3678664A1 (en) 2020-07-15
JP2020533296A (ja) 2020-11-19
CA3075020C (en) 2021-12-07
AU2018329628B2 (en) 2021-04-22
BR112020004622A2 (pt) 2020-09-24
CN111343982A (zh) 2020-06-26
US11000519B2 (en) 2021-05-11
CA3075020A1 (en) 2019-03-14
WO2019050775A1 (en) 2019-03-14
MX2020002645A (es) 2021-06-10

Similar Documents

Publication Publication Date Title
MX383462B (es) Pridopidina para el tratamiento de las discinesias inducidas por fármacos
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EA201890571A1 (ru) Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
AR086582A1 (es) Anticuerpos anti-kir para el tratamiento de trastornos inflamatorios y autoinmunes
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
UY38506A (es) Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
BR112019000635A2 (pt) inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória